Document Detail


Targeting for cardioplegia: arresting agents and their safety.
MedLine Citation:
PMID:  19492439     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Elective temporary cardiac arrest (cardioplegia) is often required during cardiac surgery. In the 1970 s, the development of hyperkalaemic cardioplegic solutions revolutionised cardiac surgery by offering effective chemically-induced cardiac arrest and myocardial protection during global ischaemia. Despite remaining the most widely-used cardioplegic technique, hyperkalaemia can have detrimental effects due to the Na and Ca loading of the cardiac cell induced by depolarisation of the cell membrane. Efforts over the last two decades to establish better cardioplegic agents have mainly remained limited to animal experiments. The failure of these approaches to progress to clinical trials may be due to a lack of clear criteria that a cardioplegic agent should meet at a cellular level and, more importantly, at a system level. In this review we attempt to define the criteria for the optimal cardioplegic agent. We also assess the suitability and clinical potential of previously-studied cardioplegic agents and suggest cellular targets, particularly those involved in cardiac excitation-contraction coupling, that may prove to be attractive options for the development of new cardioplegic drugs. Finally, we propose a multicellular target approach using a combination of pharmacological agents in order to offer better cardioplegic solutions.
Authors:
Hazem B Fallouh; Jonathan C Kentish; David J Chambers
Related Documents :
1947909 - Decreased liberation of noradrenaline from the heart following cold crystalloid cardiop...
10969689 - The temperature dependence of cardioplegic distribution in the canine heart.
15387489 - Magnesium decreases cardiac injury in patients undergoing coronary artery bypass surgery.
22626969 - Left ventricular aneurysm and differential diagnosis with pseudoaneurysm.
8419709 - Impaired endothelium-dependent coronary microvascular relaxation after cold potassium c...
6979319 - Myocardial protection with cold cardioplegia in a patient with cold autoagglutinins and...
22982779 - Disruption of nox2 and tnfrp55/p75 eliminates cardioprotection induced by anisomycin.
22651809 - Spatial pattern of p waves in paroxysmal atrial fibrillation patients in sinus rhythm a...
9932209 - Evaluation and management of pulmonary atresia with intact ventricular septum.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in pharmacology     Volume:  9     ISSN:  1471-4892     ISO Abbreviation:  Curr Opin Pharmacol     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-06-02     Completed Date:  2009-06-23     Revised Date:  2014-02-19    
Medline Journal Info:
Nlm Unique ID:  100966133     Medline TA:  Curr Opin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  220-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Calcium Channel Agonists / pharmacology
Calcium Channel Blockers / pharmacology
Cardioplegic Solutions / adverse effects*,  pharmacology*
Drug Delivery Systems
Heart Arrest, Induced / methods,  standards*
Humans
Potassium Channels / drug effects
Propanolamines / pharmacology,  therapeutic use
Grant Support
ID/Acronym/Agency:
G0001112//Medical Research Council
Chemical
Reg. No./Substance:
0/Calcium Channel Agonists; 0/Calcium Channel Blockers; 0/Cardioplegic Solutions; 0/Potassium Channels; 0/Propanolamines; MDY902UXSR/esmolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Distinct interactions of 2'- and 3'-O-(N-methyl)anthraniloyl-isomers of ATP and GTP with the adenyly...
Next Document:  Consequences of sleep deprivation on neurotransmitter receptor expression and function.